Perseo pharma AG

About Perseo pharma AG

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

What does Perseo pharma AG do?

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

Where is Perseo pharma AG located?

Perseo pharma AG is based in Basel, Switzerland.

When was Perseo pharma AG founded?

Perseo pharma AG was founded in 2019.

How much funding has Perseo pharma AG raised?

Perseo pharma AG has raised 410000.

Location
Basel, Switzerland
Founded
2019
Funding
410000
Employees
10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Perseo pharma AG

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

perseo-pharma.com700+
cb
Crunchbase
Founded 2019Basel, Switzerland

Funding

$

Estimated Funding

$300K+

Team (10+)

No team information available.

Company Description

The startup has developed a drug discovery and delivery platform that utilizes proprietary nanotechnology to create oral enzyme therapies. This technology protects enzymes with a nano-shield and targets them to the mucus of the small intestine, reducing the need for multiple pills in the treatment of digestive diseases.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.